McKESSON CORPORATION (MCK) FY2025 YTD Q3 P&L / Income Statement

McKESSON CORPORATION (MCK) FY2025 YTD Q3 P&L / Income Statement

Income statement for 2024-04-01 through 2024-12-31. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

268,228,000,000 US dollars

Cost of sales

258,544,000,000 US dollars

Gross profit

9,684,000,000 US dollars

Total operating expenses

6,853,000,000 US dollars

Operating income

2,831,000,000 US dollars

Other income (expense), net (calculated)

13,000,000 US dollars

Income before income taxes

2,844,000,000 US dollars

Income tax benefit (expense)

669,000,000 US dollars

Net income

2,175,000,000 US dollars

U.S. Pharmaceutical

244,551,000,000 US dollars

Prescription Technology Solutions

3,877,000,000 US dollars

Medical-Surgical Solutions

8,533,000,000 US dollars

International

11,260,000,000 US dollars

Corporate

7,000,000 US dollars

Selling, distribution, general, and administrative expenses

6,532,000,000 US dollars

Claims and litigation charges, net

108,000,000 US dollars

Restructuring, impairment, and related charges, net

213,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to McKESSON CORPORATION: $2.04 B; to noncontrolling interests: $140.00 M.